The FDA has approved changes to the drug label of the anti-seizure drug ezogabine (Potiga), underscoring risks of abnormalities to the retina in the eye, potential vision loss, and skin discoloration-all of which may become permanent.
Rose Schneider Krivich
Advertisement
Rose is the content specialist for Medical Economics.
Articles by Rose Schneider Krivich
Advertisement
Latest Updated Articles
- Anti-seizure drug gets boxed warning for eye damage risks
Published: November 13th 2013 | Updated:
Advertisement
Advertisement
